Gyongyi Szabo MD, PhD, FAASLD, AGAF, FACPMitchell Rabkin, MD Chair, Professor of Medicine and Faculty Dean for Academic Affairs, Harvard Medical School; Chief Academic Officer of Beth Israel Deaconess Medical Center and Beth Israel Lahey Health, Boston, Massachusetts
Gyongyi Szabo, MD, PhD, is the Mitchell T. Rabkin, M.D. Chair, Professor of Medicine and Faculty Dean at Harvard Medical School and Chief Academic Officer of the Beth Israel Deaconess Medical Center and the Beth Israel Lahey Health System. Her laboratory studies the cellular and molecular mechanisms of inflammation and innate immunity in liver injury to identify therapeutic targets focused on non-alcoholic liver disease, NASH and alcoholic liver disease. Her investigations recently revealed the importance of micro-RNAs and extracellular vesicles in liver diseases. Dr. Szabo’s group made the novel discovery that NLRP3 activation and the IL-1ß pathway are potential therapeutic targets in alcoholic hepatitis and NASH. Her translational studies with the use of IL-1 receptor antagonist provided basis for first-time clinical trials in alcoholic hepatitis with IL-1 inhibition. Dr. Szabo has mentored over 50 trainees in research, particularly clinician scientists. She is member of the Hungarian Academy of Sciences, Past President of the American Association for the Study of Liver Diseases (AASLD) and the inaugural Editor-in-Chief of Hepatology Communications.